The IRAK1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma cell line, featuring targeted disruption of the IRAK1 gene. This product offers a heterogeneous pool of cells with varied IRAK1 knockout genotypes, allowing researchers to assess IRAK1 loss-of-function effects in a context that avoids clonal artifacts and maintains population diversity.
SK-HEP-1 is a human liver adenocarcinoma cell line with prominent endothelial characteristics, including expression of markers and functional properties akin to liver sinusoidal endothelial cells. Its dual hepatic-endothelial phenotype makes it a widely used model for liver disease research, particularly hepatocellular carcinoma, hepatic inflammation, and tumor?Cendothelial interactions.
IRAK1 is a serine/threonine kinase that acts as a critical signal transducer in the MyD88-dependent innate immune pathway downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R). Upon stimulation by upstream activators such as IL-1??, LPS, or TNF-??, IRAK1 is recruited to the receptor complex, where it interacts with MyD88 and is phosphorylated by IRAK4. This triggers autophosphorylation and recruitment of TRAF6, leading to the activation of TAK1 and subsequent IKK and MAP kinase cascades. These events culminate in the activation of NF-??B and AP-1 transcription factors, driving the expression of pro-inflammatory cytokines including IL-6, TNF-??, and IL-8. IRAK1 also forms complexes with Pellino-1, TAB2, and NEMO to modulate signaling intensity, thereby linking extracellular inflammatory signals to transcriptional programs that regulate inflammation, apoptosis, and cell survival.
In the SK-HEP-1 liver adenocarcinoma context, disruption of IRAK1 is particularly relevant for investigating the contribution of TLR/IL-1R signaling to hepatic inflammation and cancer progression. Given the liver??s constant exposure to endotoxins and cytokines, IRAK1-mediated signaling may foster a pro-tumorigenic inflammatory microenvironment. The knockout model enables dissection of IRAK1-dependent cytokine production, NF-??B activation, and MAP kinase activity in cells that exhibit both malignant and endothelial features, thereby revealing potential vulnerabilities in hepatocellular carcinoma.
These polyclonal IRAK1 knockout cells are suitable for a range of applications, including functional studies of TLR/IL-1R signaling in liver cancer, drug target validation for inflammatory disorders and hepatic malignancies, and mechanistic analysis of IRAK1-dependent pathways. Representative assays include Western blotting for IRAK1 and phospho-p65, RT-qPCR for IL-6 and TNF-??, NF-??B luciferase reporter, MTT or CellTiter-Glo proliferation, flow cytometry for apoptosis (Annexin V), and cytokine ELISA (IL-6, IL-8). For additional specifications, please contact Ascent Research.
